Biotech is one of the hottest sectors right now.
Several biotech companies are already up more than 380% since the beginning of the year. And one, Axsome Therapeutics, is up more than 800%!
In this six-minute video, they discuss:
- The biotech industry has the potential for enormous gains. However, companies can rapidly lose value if their drug isn’t approved. Quote: “Biotech generally has somewhat of a scary reputation for many investors.”
- A small-cap biotech company can have several outcomes. Sometimes new biotech firms get bought out by one of the industry’s major players. Quote: “Knowing which route your investment is going to take is critical.”
- Take a look at companies that sell equipment to biotech firms. These “pick and shovel” companies offer products or services that improve the process of developing new drugs. Quote: “I think that’s a key way that lots of people can move into this sector.”
Watch the six-minute video below to hear how Jeff and Ted find the big winners while avoiding the flops.
Breaking News: Massive Biotech Breakthrough
I’m glad we talked about the biotech boom today because it reminded me of something Jeff brought up recently.
See, over 50 million Americans suffer from allergies. (I’m one of them.) And when someone has a severe allergic reaction, he or she can lose the ability to breathe within seconds.
It’s scary. And sadly, thousands of people in the U.S. have died from allergic reactions in recent years. But Jeff recently told me about a biotech company that has the solution to this.
He’s been talking to their executives about it for over a year.
The solution lies in a cutting-edge medical device that’s essential for those who suffer from allergies, seizures, heart disease or a number of other life-threatening ailments. It’s small enough that you can carry one in your pocket.
Luckily, it’s already fully patented and approved by the Food and Drug Administration.
That’s great for all the allergy suffers out there, and it’s also great for investors.
In fact, Jeff told me he’s confident this device will go down in history as one of the most important medical breakthroughs ever.
But not many investors know about it yet. That means you still have a chance to buy shares of this biotech company now at a rock-bottom price.
Jeff predicts the stock will quickly triple in price and then only soar higher from there. So, I suggest acting fast.
And remember to read below for a wrap-up of this week’s Sovereign Investor Daily articles.
Assistant Managing Editor, Banyan Hill Publishing